title: Targeting insulin-like growth factor pathways.
abstract: Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.
authors.affiliation: University of Minnesota Cancer Center, Department of Medicine, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA. yeexx006@umn.edu
authors.forename: D
authors.initials: D
authors.lastname: Yee
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D017526:Receptor, IGF Type 1 / Q000187:drug effects* / Q000502:physiology*; D012107:Research Design; D015398:Signal Transduction
chemical_list: D014408:Biomarkers, Tumor; D017526:Receptor, IGF Type 1